Abstracts tagged "Systemic sclerosis"

Abstract Number: 2515 • ACR Convergence 2023
Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases
Shinji Izuka¹, Toshihiko Komai¹, Takahiro Itamiya¹, Mineto Ota², Saeko Yamada¹, Yasuo Nagafuchi², Hirofumi Shoda¹, Kosuke Matsuki³, Kazuhiko Yamamoto⁴, Tomohisa Okamura⁵ and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama City, Japan, ⁴Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁵Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Mixed connective tissue disease (MCTD) is a heterogenous autoimmune disorder with overlapping clinical features of systemic lupus erythematosus (SLE), polymyositis/dermatomyositis, and systemic sclerosis (SSc).…
Abstract Number: 0127 • ACR Convergence 2023
Time Trends, Cumulative Incidence, and Impact on Survival of Interstitial Lung Disease in Systemic Sclerosis: Results from a Population-based Cohort Study
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Cardiopulmonary complications are the number one cause of mortality in Systemic sclerosis (SSc). We studied the prevalence, cumulative incidence, predictors and impact of interstitial…
Abstract Number: 0621 • ACR Convergence 2023
Scleroderma Renal Crisis: A Large Single-center Experience
Rushab Shah¹, laura ross², Kathleen Morrisroe³, Wendy Stevens⁴ and Mandana Nikpour⁵, ¹St Vincent's Hospital Melbourne/ Alfred Hospital, Melbourne, Australia, ²St. Vincent's Hospital Melbourne, Fitzroy, Australia, ³The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, ⁴Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ⁵The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening vascular manifestation of systemic sclerosis (SSc) occurring in up to 5% of SSc patients. This condition continues…
Abstract Number: 0641 • ACR Convergence 2023
The Evaluation of Lower Extremities Arterial Disease in Systemic Sclerosis Patients Through Rheumatologist-Vascular Surgeon Multidisciplinary Management: Preliminary Data from an Italian Single Center Study
Maria Grazia Lazzaroni¹, Liala Moschetti¹, Eleonora Pedretti¹, Paolo Baggi², Franco Franceschini³, Stefano Bonardelli² and Paolo Airò¹, ¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ²Vascular Surgery, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
Background/Purpose: The occurrence of lower limbs macrovascular complications configuring lower extremities arterial disease (LEAD) has been reported in Systemic Sclerosis (SSc) patients. Recently, digital ulcers…
Abstract Number: 0662 • ACR Convergence 2023
Changes in Treatment Patterns and Their Influence on the Outcome of Systemic Sclerosis-interstitial Lung Disease (SSc-ILD) Patients: An EUSTAR Analysis
Corrado Campochiaro¹, Marie-Elise Truchetet², Madelon Vonk³, Giovanna Cuomo⁴, Lidia P Ananieva⁵, Eric Hachulla⁶, Vanessa Smith⁷, Ana Maria Gheorghiu⁸, Radim Becvar⁹, Nicolas Hunzelmann¹⁰, Daniel Furst¹¹, Vera Ortiz-Santamaria¹², Patricia Carreira¹³, Francesco Del Galdo¹⁴, marco Matucci Cerinic¹⁵ and Anna Maria Hoffmann-Vold¹⁶, ¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ⁵V.A. Nasonova Research Institute Of Rheumatology Russian Federation, Moscow, Russia, ⁶University of Lille, Lille, France, ⁷Ghent University Hospital, Gent, Belgium, ⁸Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, ⁹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ¹⁰University of Kšln, Kšln, Germany, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Granollers, Granollers, Spain, ¹³Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁴University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ¹⁵Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁶Oslo University Hospital, Department of Rheumatology, Oslo, Norway
Background/Purpose: The treatment armamentarium with immunosuppressive treatments (ISTs) for interstitial lung disease (ILD) in systemic sclerosis (SSc) has greatly expanded. It is to date unclear…
Abstract Number: 0937 • ACR Convergence 2023
IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice
Ji Won Yang¹, Kun Hee Lee², Jin Seok Woo², Ha Yeon Jeong², JeongWon Choi², Eui-Jong Kwon¹, Mi-La Cho² and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Systemic sclerosis (SS), also known as scleroderma, is a chronic autoimmune disease caused by inflammation, tissue fibrosis, and vasculopathy. Although the pathological mechanisms of…
Abstract Number: 0960 • ACR Convergence 2023
MiR-3606-3p Alleviates Skin Fibrosis by Suppressing Fibroblast Inflammation and Migration via Inhibiting GAB1 and ITGAV
yahui chen¹, Mengkun shi¹, Wei Wang¹, Chenyi Shi¹, Xueyi Xia¹, wenyu Wu², Jiucun Wang³ and Xiangguang Shi³, ¹Fudan University, Shanghai, China, ²Huashan Hospital, Shanghai, China, ³Shanghai, Shanghai, China
Background/Purpose: Systemic sclerosis (SSc) and keloid are typical skin fibrotic diseases with unclear epigenetic mechanisms and clinical targets. As an important epigenetic regulatory factor, microRNAs…
Abstract Number: 1528 • ACR Convergence 2023
Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients
Francesco Bonomi¹, Arianna Damiani¹, Carmela Coccia¹, Juela Levani¹, elisa Fiorentini², silvia peretti¹, Gemma Lepri¹, martina orlandi¹, francesca bartoli¹, marco Matucci Cerinic³, silvia bellando randone¹ and serena guiducci¹, ¹Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy, ²Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Firenze, Italy, ³Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy
Background/Purpose: Treatment of systemic sclerosis (SSc) is challenging, and in the last 2 decades there has been an increasing interest for immunoglobulin (Igs) treatment as…
Abstract Number: 1897 • ACR Convergence 2023
In Pursuit of Excellence: Improving Systemic Sclerosis Quality of Care
Aos Aboabat¹, Samar Aboulenain¹, Zareen Ahmad², Medha Soowamber³ and Sindhu Johnson⁴, ¹University of Toronto, Toronto, ON, Canada, ²Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Woodbridge, ON, Canada, ⁴Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease with significant morbidity and mortality. Quality indicators (QIs) for SSc care, previously published, are essential tools…
Abstract Number: 2532 • ACR Convergence 2023
Prevalence and Disease-Specific Factors Associated with Osteoporosis in Systemic Sclerosis: A Cross-Sectional Analysis of Two Large European Cohorts
Charles MIDOL¹, Edgar Wiebe², Elise Siegert³, Dörte Huscher⁴, Helene Behal⁵, David Launay⁶, Eric Hachulla⁷, Eric Matteson⁸, Vincent Sobanski⁹ and Frank Buttgereit², ¹Lille University Hospital, Besançon, France, ²Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ³Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁴Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Univ. Lille, CHU Lille, Biostatistics Department, Lille, France, ⁶Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, Lille, France, ⁷CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ⁸Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ⁹Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France
Background/Purpose: Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. However, the risks factors and mechanisms driving bone…
Abstract Number: 0128 • ACR Convergence 2023
Incidence, Trends, and Determinants of Multimorbidity in Systemic Sclerosis: Data from a Population-based Cohort
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: To evaluate the burden, longitudinal trends, and drivers of multimorbidity (MM; the presence of ≥2 morbidities) in patients with Systemic Sclerosis (SSc) vs. age-…
Abstract Number: 0622 • ACR Convergence 2023
The Effectiveness of Breath-holding Test to Predict Pulmonary Function in Systemic Sclerosis Patients Using Machine Learning Model
Jina Yeo¹, Min Hyuk Lim², Ju Yeon Kim³, Ji In Jung⁴, Saram Lee² and Eun Bong Lee³, ¹Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, ²Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, South Korea, ³Seoul National University Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Pulmonary involvement is major causes of mortality in patients with systemic sclerosis (SSc). The breath-holding test (BHT), rapid bedside test, is a useful surrogate…
Abstract Number: 0643 • ACR Convergence 2023
Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Hilde Jenssen Bjørkekjær⁵, Cathrine Brunborg⁶, Cosimo Bruni⁷, Christian Clarenbach⁸, Phuong Phuong Diep⁹, Rucsandra Dobrota⁷, Michael Durheim¹⁰, Muriel Elhai¹¹, Thomas Frauenfelder¹², Suzana Jordan⁷, Emily Langballe¹³, Oyvind Midtvedt¹, Carina Mihai⁷, Oyvind Molberg¹⁴ and Oliver Distler⁷, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ⁶Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁹Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ¹⁰Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹¹University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹²Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹³Universitetet i Oslo, Oslo, Norway, ¹⁴Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: In clinical practice, we often wait for progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) to initiate or escalate therapy. Similarly, progressive…
Abstract Number: 0663 • ACR Convergence 2023
Vaccine-Preventable Diseases in Hospitalized Patients with Systemic Sclerosis: A Nationwide Cohort Analysis
Saman Tanveer, Chun Pan and Faria Sami, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Connective tissue disorders, including systemic sclerosis (SSc), are associated with an increased risk of infections. Infections are the most common diagnosis during hospitalizations and…
Abstract Number: 0938 • ACR Convergence 2023
Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum
Sunhwa Kim¹, Thierry Sornasse², Vishal Kakkar³, Rebecca Ross⁴, Yingtao Bi⁵, Hengcheng Hu², Lisa Hazelwood², Lauren Reinke-Breen⁶, jozsef karman⁷, Chris Butler², Jennifer Van Camp² and Francesco Del Galdo⁸, ¹AbbVie, Inc., South San Francisco, CA, ²AbbVie, Inc., North Chicago, IL, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁵AbbVie, Inc., Worcester, MA, ⁶AbbVie, Inc., Vernon Hills, IL, ⁷AbbVie, Inc., San Francisco, CA, ⁸University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs asynchronously, leading to highly variable fibrotic damage and consequent increased morbidity and mortality.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].